Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Derk C.F. Klatte

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2531-6725; OpenAlex author ID A5015175917. Sources: OpenAlex.

Their work

Papers
19 (first author 6, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2022: 3 papers · 2023: 2 papers · 2024: 6 papers · 2025: 5 papers · 2026: 3 papers

Papers 19

  1. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. First author DOI 10.1016/j.eclinm.2026.103755↗
  2. Longitudinal body composition changes distinguish pancreatic ductal adenocarcinoma from controls in a pre-diagnostic CT cohort. First author DOI 10.1016/j.pan.2026.09.008↗
  3. Association Between Computed Tomography-Based AI-Derived Body Composition and Survival in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.14309/ajg.0000000000003896↗
  4. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. First author DOI 10.1007/s10689-025-00512-5↗
  5. Recommendations, evidence and sustainability of screening for pancreatic cancer in high-risk individuals. Last author DOI 10.1016/j.bpg.2025.101974↗
  6. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Co-author DOI 10.1016/j.cgh.2024.07.048↗
  7. Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases. First author DOI 10.1097/mpa.0000000000002517↗
  8. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  9. Psychosocial issues of individuals undergoing surveillance for increased risk of melanoma and pancreatic cancer due to a germline CDKN2A variant: A focus group… Co-author DOI 10.1002/jgc4.1820↗
  10. Pancreatic cancer surveillance: Risk stratification of individuals with a germline CDKN2A pathogenic variant. Co-author DOI 10.1002/ueg2.12662↗
  11. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer. Co-author DOI 10.1007/s10689-024-00368-1↗
  12. Temporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cgh.2024.03.038↗
  13. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1097/mpa.0000000000002335↗
  14. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op.23.00447↗
  15. Identification of individuals at high-risk for pancreatic cancer using a digital patient-input tool combining family cancer history screening and new-onset dia… Co-author DOI 10.1016/j.pmedr.2023.102110↗
  16. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  17. Hereditary pancreatic cancer. Co-author DOI 10.1016/j.bpg.2021.101783↗
  18. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. First author DOI 10.1016/j.pan.2022.03.021↗
  19. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Co-author DOI 10.1200/jco.22.00194↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Monique Esther van Leerdam · 15 shared papers, 2022–2026 · strength 3.24
  2. Michael B. Wallace · 10 shared papers, 2022–2026 · strength 2.30
  3. Jeanin Elise van Hooft · 11 shared papers, 2022–2026 · strength 2.26
  4. Aleksander M. Bogdanski · 7 shared papers, 2024–2026 · strength 1.75
  5. Bert A. Bonsing · 6 shared papers, 2022–2025 · strength 1.02
  6. Yan Bi · 4 shared papers, 2024–2026 · strength 1.00
  7. Thomas P. Potjer · 5 shared papers, 2022–2024 · strength 0.90
  8. J. Sven D. Mieog · 4 shared papers, 2022–2026 · strength 0.74
  9. Bas Boekestijn · 4 shared papers, 2022–2024 · strength 0.70
  10. Martin N.J.M. Wasser · 4 shared papers, 2022–2024 · strength 0.70
  11. Hans F. A. Vasen · 4 shared papers, 2022–2024 · strength 0.58
  12. Marco J. Bruno · 3 shared papers, 2022–2024 · strength 0.58
  13. Douglas L. Riegert‐Johnson · 2 shared papers, 2024–2025 · strength 0.40
  14. Djuna L. Cahen · 2 shared papers, 2022–2024 · strength 0.38
  15. Sanne A.M. Hoogenboom · 2 shared papers, 2023–2025 · strength 0.38
  16. Megan M.L. Engels · 2 shared papers, 2024–2025 · strength 0.37
  17. Manfred Wuhrer · 2 shared papers, 2022–2025 · strength 0.35
  18. Yuri E. M. van der Burgt · 2 shared papers, 2022–2025 · strength 0.35
  19. Wilma E. Mesker · 2 shared papers, 2022–2025 · strength 0.35
  20. Lydia G. van der Geest · 2 shared papers, 2023–2025 · strength 0.34
  21. Pilar Acedo · 1 shared paper, 2025 · strength 0.33
  22. Che G. Ngufor · 1 shared paper, 2026 · strength 0.29
  23. Koen J.H. Wijsman · 1 shared paper, 2026 · strength 0.28
  24. Hani M. Babiker · 1 shared paper, 2026 · strength 0.28
  25. Hans Morreau · 2 shared papers, 2022–2023 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.